Premium
Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors *
Author(s) -
Rizza C. R.,
Fletcher M. L.,
Kernoff P. B. A.
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb03063.x
Subject(s) - medicine , haemophilia , haemophilia a , hepatitis b , thrombosis , haemophilia b , human immunodeficiency virus (hiv) , blood transfusion , hematology , hepatitis , risk factor , hepatitis c , hepatitis virus , virology , gastroenterology , surgery
Summary. Twenty‐seven factor VIII deficient patients who had previously not been treated with blood or blood products were studied after infusion of a total of 24 batches of NHS factor VIII (8Y) concentrate produced by Bio‐Products Laboratory, Elstree. Follow‐up was carried out according to guidelines laid down by the International Society for Thrombosis and Haemostasis. Serial estimations of amino transferase level carried out over a 26‐week period revealed no elevation of these enzymes attributable to hepatitis. Studies of various virological markers found no evidence of infection with hepatitis C, hepatitis B or HIV following transfusion. This confirms a previous finding that severe dry heating of factor VIII at 80°C for 72 h seems to reduce the risk of transmitting hepatitis C from approximately 90% to a rate of 0–11%.